On Jun. 17, 2021, the Biden Administration is investing more than $3 billion to accelerate the discovery, development and manufacturing of antiviral medicines. As part of the plan, the NIH planned to evaluate, prioritize and advance antiviral candidates to Phase 2 clinical trials.